In the last trading session, 2.49 million Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) shares changed hands as the company’s beta touched 0.28. With the company’s per share price at $1.49 changed hands at -$0.02 or -1.32% during last session, the market valuation stood at $238.44M. IRWD’s last price was a discount, traded about -519.46% off its 52-week high of $9.23. The share price had its 52-week low at $1.34, which suggests the last value was 10.07% up since then. When we look at Ironwood Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 2.63 million shares, with the 3-month average coming to 3.25 million.
Analysts gave the Ironwood Pharmaceuticals Inc (IRWD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IRWD as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Ironwood Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.01.
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) trade information
Instantly IRWD was in red as seen at the end of in last trading. With action -0.67%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -66.37%, with the 5-day performance at -0.67% in the red. However, in the 30-day time frame, Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) is -23.20% down. Looking at the short shares, we see there were 12.05 million shares sold at short interest cover period of 2.59 days.
The consensus price target for the stock as assigned by Wall Street analysts is 7, meaning bulls need an upside of 78.71% from its current market value. According to analyst projections, IRWD’s forecast low is 7 with 7 as the target high. To hit the forecast high, the stock’s price needs a -369.8% plunge from its current level, while the stock would need to soar -369.8% for it to hit the projected low.
Ironwood Pharmaceuticals Inc (IRWD) estimates and forecasts
Year-over-year growth is forecast to reach -18.31% down from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 67.02M. 5 analysts are of the opinion that Ironwood Pharmaceuticals Inc’s revenue for the current quarter will be 73.08M. The company’s revenue for the corresponding quarters a year ago was 74.88M and 94.4M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -10.49%. The estimates for the next quarter sales put growth at -22.58%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -40.82%. The 2025 estimates are for Ironwood Pharmaceuticals Inc earnings to increase by 325.00%.
IRWD Dividends
Ironwood Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.80% of Ironwood Pharmaceuticals Inc shares while 104.53% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 106.45%. There are 104.53% institutions holding the Ironwood Pharmaceuticals Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 14.5067% of the shares, roughly 22.88 million IRWD shares worth $149.16 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 13.6737% or 21.56 million shares worth $140.59 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were Pacer Small Cap U.S. Cash Cows 100 ETF and iShares Core S&P Smallcap ETF . With 11.05 shares estimated at $16.46 million under it, the former controlled 6.90% of total outstanding shares. On the other hand, iShares Core S&P Smallcap ETF held about 5.66% of the shares, roughly 9.06 shares worth around $13.49 million.
